Form 4: Nuvalent CFO Alexandra Balcom Executes Stock Option and Sells Shares
SEC Form 4 Filing
Alexandra Balcom, CFO of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on June 28, 2024, according to a recent SEC Form 4 filing.
Summary
- On June 28, 2024, Alexandra Balcom, the Chief Financial Officer of Nuvalent, Inc., engaged in transactions involving the company's Class A Common Stock.
- Balcom exercised a stock option to acquire 10,000 shares at a price of $27.85 per share.
- Simultaneously, Balcom sold a total of 10,000 shares in multiple transactions at weighted average prices of $75.15, $76.19 and $76.73.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 28, 2023.
- Following these transactions, Balcom directly owns 33,300 shares of Class A Common Stock and holds options for 134,200 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There's no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly traded companies, and the disclosed transactions are typical for executives managing their equity compensation.
- The use of Rule 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations, similar to practices observed at companies like Amgen, Regeneron, and Vertex Pharmaceuticals.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a key executive, but the pre-arranged nature of the trades mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2023-12-28 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-06-28 | Date of stock option exercise and share sales. |
| 2024-07-02 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.